Drug and stem cells delivery to salivary glands – a concise review
Advancements in drug and stem cell delivery systems for SGs offer the potential to move beyond symptomatic relief and instead regenerate damaged tissues. These approaches promise more targeted, cost-effective, and long-lasting therapies, though challenges like immune rejection, safety, and cost remain significant. Future research should focus on improving stem cell sources, delivery, and tracking, while integrating technologies such as gene editing, nanocarriers, and tissue engineering to enhance efficacy. Ultimately, treatment strategies are shifting toward regenerative solutions aimed at restoring SG function with fewer systemic side effects.
Authors
- Mohammed Badwelan (ORCID: https://orcid.org/0000-0001-8101-0531)
- Yuanyuan Peng (ORCID: https://orcid.org/0000-0003-2852-1951)
- Yoshinori Sumita (ORCID: https://orcid.org/0000-0002-1247-9763)
- Janaki Iyer (ORCID: https://orcid.org/0000-0003-2033-7391)
- Riho Kanai (ORCID: https://orcid.org/0009-0008-8779-9535)
- Arvind Hariharan (ORCID: https://orcid.org/0000-0003-2204-2618)
- Simon D. Tran (ORCID: https://orcid.org/0000-0001-5594-359X)
Institutions
- McGill University Health Centre (CA)
- Nagasaki University (JP)
- McGill University (CA)
Publication Details
- Journal
- Expert Opinion on Drug Delivery
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1080/17425247.2025.2569641
- Primary Topic
- Salivary Gland Disorders and Functions
- Type
- article
- Field-Weighted Citation Impact
- 0.00